Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

The costs of Alzheimer's disease and the value of effective therapies.

Stefanacci RG.

Am J Manag Care. 2011 Nov;17 Suppl 13:S356-62. Review.

3.

The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.

Bond M, Rogers G, Peters J, Anderson R, Hoyle M, Miners A, Moxham T, Davis S, Thokala P, Wailoo A, Jeffreys M, Hyde C.

Health Technol Assess. 2012;16(21):1-470. doi: 10.3310/hta16210. Review.

4.

Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.

Mucha L, Shaohung S, Cuffel B, McRae T, Mark TL, Del Valle M.

J Manag Care Pharm. 2008 Jun;14(5):451-61.

5.

Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses.

Pouryamout L, Dams J, Wasem J, Dodel R, Neumann A.

Drugs. 2012 Apr 16;72(6):789-802. doi: 10.2165/11631830-000000000-00000. Review.

PMID:
22480339
6.

Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada.

O'Brien BJ, Goeree R, Hux M, Iskedjian M, Blackhouse G, Gagnon M, Gauthier S.

J Am Geriatr Soc. 1999 May;47(5):570-8.

PMID:
10323651
7.

Effective pharmacological management of Alzheimer's disease.

Atri A.

Am J Manag Care. 2011 Nov;17 Suppl 13:S346-55. Review.

8.

Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review.

Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, Waugh N.

Int J Technol Assess Health Care. 2002 Summer;18(3):497-507. Review.

PMID:
12391943
9.

Donepezil use in managed Medicare: effect on health care costs and utilization.

Fillit H, Gutterman EM, Lewis B.

Clin Ther. 1999 Dec;21(12):2173-85.

PMID:
10645761
10.

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.

Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E, Clegg A.

Health Technol Assess. 2006 Jan;10(1):iii-iv, ix-xi, 1-160. Review.

11.

Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States.

Migliaccio-Walle K, Getsios D, Caro JJ, Ishak KJ, O'Brien JA, Papadopoulos G; AHEAD Study Group..

Clin Ther. 2003 Jun;25(6):1806-25.

PMID:
12860500
12.

An economic evaluation of donepezil in the treatment of Alzheimer's disease.

Small GW, Donohue JA, Brooks RL.

Clin Ther. 1998 Jul-Aug;20(4):838-50.

PMID:
9737841
13.

Treatment of Alzheimer's disease in the long-term-care setting.

Smith DA.

Am J Health Syst Pharm. 2009 May 15;66(10):899-907. doi: 10.2146/ajhp070622. Review.

PMID:
19420308
14.

The use, benefits, and costs of cholinesterase inhibitors for Alzheimer's dementia in long-term care: are the data relevant and available?

Khang P, Weintraub N, Espinoza RT.

J Am Med Dir Assoc. 2004 Jul-Aug;5(4):249-55. Review. No abstract available.

PMID:
15228635
15.

Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan.

Fuh JL, Wang SJ.

Int J Geriatr Psychiatry. 2008 Jan;23(1):73-8.

PMID:
17520661
16.

Galantamine: a pharmacoeconomic review of its use in Alzheimer's disease.

Lyseng-Williamson KA, Plosker GL.

Pharmacoeconomics. 2002;20(13):919-42.

PMID:
12381243
17.

Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation.

Hartz S, Getsios D, Tao S, Blume S, Maclaine G.

BMC Neurol. 2012 Feb 8;12:2. doi: 10.1186/1471-2377-12-2.

18.

An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial.

Wimo A, Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wetterholm AL, Mastey V, Haglund A, Zhang R, Miceli R, Chin W, Subbiah P; Donepezil Nordic Study Group..

Dement Geriatr Cogn Disord. 2003;15(1):44-54. Erratum in: Dement Geriatr Cogn Disord. 2003;16(2):102.

PMID:
12457078
19.

Economic evaluation of donepezil in moderate to severe Alzheimer disease.

Feldman H, Gauthier S, Hecker J, Vellas B, Hux M, Xu Y, Schwam EM, Shah S, Mastey V; Donepezil MSAD Study Investigators Group..

Neurology. 2004 Aug 24;63(4):644-50.

PMID:
15326236
20.

Supplemental Content

Support Center